Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3334292 | Surgical Pathology Clinics | 2016 | 13 Pages |
Abstract
Molecular testing in colorectal cancer helps to address multiple clinical needs. Evaluating the mismatch repair pathway status is the most common use for molecular diagnostics and this testing provides prognostic information, guides therapeutic decisions and helps identify Lynch syndrome patients. For patients with metastatic colorectal cancer, testing for activating mutations in downstream components of the EGFR signaling pathway can identify patients who will benefit from anti-EGFR therapy. Emerging molecular tests for colorectal cancer will help further refine patient selection for targeted therapies and may provide new options for monitoring disease recurrence and the development of treatment resistance.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Jonathan A. Nowak, Jason L. Hornick,